Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 233-343-1 | CAS number: 10124-56-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- abstract
- Justification for type of information:
- A scientific review.
Data source
Referenceopen allclose all
- Reference Type:
- review article or handbook
- Title:
- Final Report on the Safety Assessment of Sodium Metaphosphate, Sodium Trimetaphosphate, and Sodium Hexametaphosphate
- Author:
- Reviewed by the Cosmetic Ingredient Review Expert Panel.
- Year:
- 2 001
- Bibliographic source:
- International Journal of Toxicology, p 75-89.
- Reference Type:
- review article or handbook
- Title:
- Summaries of toxicological data: Toxicity studies on phosphates .
- Year:
- 1 964
- Bibliographic source:
- Food Cosmet. Toxicol. 2:147–154.
Materials and methods
- Principles of method if other than guideline:
- No information on the method. Male and female weanling rats (50 per group) were fed basal diet plus 0.05%, 0.5%, or 5.0% Sodium Hexametaphosphate.
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Sodium metaphosphate
- EC Number:
- 233-343-1
- EC Name:
- Sodium metaphosphate
- Cas Number:
- 10124-56-8
- Molecular formula:
- Na6O18P6
- IUPAC Name:
- hexasodium 2,4,6,8,10,12-hexaoxocyclohexaphosphoxane-2,4,6,8,10,12-hexakis(olate)
Constituent 1
Test animals
- Species:
- rat
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: feed
- No. of animals per sex per dose:
- 50
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Rats fed 0.5% to 5.0% Sodium Hexametaphosphate had increased kidney to body weight ratios. Renal infections were observed more frequently in rats of groups given Sodium Hexametaphosphate than in rats of the control group. Female rats of the high-dose group had “possibly increased” lung weights and decreased splenic weights. The incidence of renal infection made diffcult the interpretation of organ weights.
One female rat fed 0.5% Sodium Hexametaphosphate, and 13 of 20 rats given 5.0% Sodium Hexametaphosphate had calcination of the renal tubules. - Mortality:
- mortality observed, treatment-related
- Description (incidence):
- A dose-related increase in mortality was not observed during the test period; however, overall mortality was 64% to 78% (females surviving better than males). The median life span was greatest in males given the medium dose of Sodium Hexametaphosphate. The most common cause of death was respiratory infection.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Rats of the control group had no observed effects on growth. Of rats given the low and median doses of Sodium Hexametaphosphate, no adverse effect swere noted.
Males of the high-dose group had reduced growth, but females of the same group were only slightly affected. Rats of the high-dose group had greater feed consumption at days 90 and 210, as compared to rats of the control group. - Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- Hematologic parameters did not differ from those of controls.
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- Only traces of protein and reducing substances were found in the urine.
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Rats fed 0.5% to 5.0% Sodium Hexametaphosphate had increased kidney to body weight ratios. Renal infections were observed more frequently in rats of groups given Sodium Hexametaphosphate than in rats of the control group. Female rats of the high-dose group had “possibly increased” lung weights and decreased splenic weights. The incidence of renal infection made diffcult the interpretation of organ weights.
- Gross pathological findings:
- not specified
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- not specified
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- effects observed, treatment-related
- Description (incidence and severity):
- The femur lengths were not significantly affected by treatment with Sodium Hexametaphosphate. The femurs of all rats had comparable water, ash, calcium, and phosphorus contents, and appeared normal in radiograph.
Applicant's summary and conclusion
- Conclusions:
- No adverse effects were noted at male and female rats given the low and median doses (0.05 and 0.5%) of Sodium Hexametaphosphate (2 years study).
- Executive summary:
No adverse effects were noted at male and female rats given the low and median doses (0.05 and 0.5%) of Sodium Hexametaphosphate (2 years study).
A dose-related increase in mortality was not observed during the test period; however, overall mortality was 64% to 78% (females surviving better than males). The median life span was greatest in males given the medium dose of Sodium Hexametaphosphate.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.